Literature DB >> 34289955

Cost-Effectiveness Analysis of Michigan's School-Wide Sexually Transmitted Disease Screening Program in Four Detroit High Schools.

Li Yan Wang1, Amy Peterson2, Jingjing Li3, Kenneth Coleman4, Richard Dunville3.   

Abstract

PURPOSE: The Michigan Department of Health and Human Services, in collaboration with St. John Providence Health System, initiated voluntary school-wide sexually transmitted disease (STD) screenings in four Detroit public high schools. We sought to assess the cost-effectiveness of the STD screening program from 2010 to 2015, with a focus on chlamydia.
METHODS: The costs and effectiveness of the school-based screening were compared with those of a "no school screening" scenario using a healthcare system perspective. A decision tree model was constructed to project cases of chlamydia, epididymitis, and pelvic inflammatory disease (PID) in each of the two scenarios among students tested positive and their partners. Health effects were measured as cases of PID prevented, and quality-adjusted life-years (QALYs) gained. Cost estimates included program costs, chlamydia testing/treatment costs in the absence of school screening, and treatment costs for epididymitis, PID, and PID sequelae. The incremental cost-effectiveness ratio (ICER) was measured as cost/QALY gained. Multivariate sensitivity analyses were conducted on key parameter estimates and assumptions used.
RESULTS: Under base-case assumptions, at a total program cost of $333,848 over 5 years, the program prevented an estimated 1.9 cases of epididymitis and 17.3 cases of PID, resulting in an ICER of $38,235/QALY gained (yearly ICER ranging from $27,417 to $50,945/QALY). Of 10,000 Monte Carlo simulation runs, the yearly ICER remained ≤$50,000/QALY in 64%-98% of the simulation runs.
CONCLUSIONS: We found favorable cost-effectiveness ratios for Michigan's school-wide STD screening program in Detroit. School-based STD screening programs of this type warrant careful considerations by policy makers and program planners. Published by Elsevier Inc.

Entities:  

Keywords:  Chlamydia; Cost-effectiveness; School-wide STD screening

Mesh:

Year:  2021        PMID: 34289955      PMCID: PMC9281505          DOI: 10.1016/j.jadohealth.2021.05.014

Source DB:  PubMed          Journal:  J Adolesc Health        ISSN: 1054-139X            Impact factor:   7.830


  25 in total

1.  The Philadelphia High-School STD Screening Program: key insights from dynamic transmission modeling.

Authors:  David N Fisman; C Victor Spain; Melinda E Salmon; Martin Goldberg
Journal:  Sex Transm Dis       Date:  2008-11       Impact factor: 2.830

2.  The project connect health systems intervention: linking sexually experienced youth to sexual and reproductive health care.

Authors:  Patricia J Dittus; Christine J De Rosa; Robin A Jeffries; Abdelmonem A Afifi; William G Cumberland; Emily Q Chung; Esteban Martinez; Peter R Kerndt; Kathleen A Ethier
Journal:  J Adolesc Health       Date:  2014-05-22       Impact factor: 5.012

3.  Human Immunodeficiency Virus, Chlamydia, and Gonorrhea Testing in New York Medicaid-Enrolled Adolescents.

Authors:  Li Yan Wang; Man-Huei Chang; Gale Burstein; Susan Hocevar Adkins
Journal:  Sex Transm Dis       Date:  2018-01       Impact factor: 2.830

4.  Sexually transmitted diseases treatment guidelines, 2006.

Authors:  Kimberly A Workowski; Stuart M Berman
Journal:  MMWR Recomm Rep       Date:  2006-08-04

5.  Cost-effectiveness analysis of Chlamydia trachomatis screening via internet-based self-collected swabs compared with clinic-based sample collection.

Authors:  Wei Huang; Charlotte A Gaydos; Mathilda R Barnes; Mary Jett-Goheen; Diane R Blake
Journal:  Sex Transm Dis       Date:  2011-09       Impact factor: 2.830

6.  Epidemiologic and microbiologic correlates of Chlamydia trachomatis infection in sexual partnerships.

Authors:  T C Quinn; C Gaydos; M Shepherd; L Bobo; E W Hook; R Viscidi; A Rompalo
Journal:  JAMA       Date:  1996-12-04       Impact factor: 56.272

7.  The program cost and cost-effectiveness of screening men for Chlamydia to prevent pelvic inflammatory disease in women.

Authors:  Thomas L Gift; Charlotte A Gaydos; Charlotte K Kent; Jeanne M Marrazzo; Cornelis A Rietmeijer; Julia A Schillinger; Eileen F Dunne
Journal:  Sex Transm Dis       Date:  2008-11       Impact factor: 2.830

8.  Cost-effectiveness of screening strategies for Chlamydia trachomatis using cervical swabs, urine, and self-obtained vaginal swabs in a sexually transmitted disease clinic setting.

Authors:  Diane R Blake; Nancy Maldeis; Mathilda R Barnes; Andrew Hardick; Thomas C Quinn; Charlotte A Gaydos
Journal:  Sex Transm Dis       Date:  2008-07       Impact factor: 2.830

9.  Cost-Effectiveness of a School-Based Chlamydia Screening Program, Duval County, FL.

Authors:  Li Yan Wang; Kwame Owusu-Edusei; J Terry Parker; Kristina Wilson
Journal:  J Sch Nurs       Date:  2019-12-01       Impact factor: 2.361

10.  Risk of pelvic inflammatory disease following Chlamydia trachomatis infection: analysis of prospective studies with a multistate model.

Authors:  Malcolm J Price; A E Ades; Daniela De Angelis; Nicky J Welton; John Macleod; Kate Soldan; Ian Simms; Katy Turner; Paddy J Horner
Journal:  Am J Epidemiol       Date:  2013-06-27       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.